USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies
10-Nov-2014
North America
Market Research
NEC3-01-00-00-00
LS00130-NA-MR_16971
This market insight provides data for the global multiple sclerosis (MS) market. The analysis looks at MS pharmaceutical pipeline drugs that are currently in the market as well as any drugs that are in Phase III trials and pose a potential threat to competitors. It offers a competitive analysis of these drugs and the forecasted outcome and impact of each of these drugs. Injectable drugs dominate MS drugs currently in the market, but the launch of numerous oral pipeline products can shift this market in favor of oral drugs. The MS market is segmented into relapsing, remitting, secondary progressive, primary progressive, and progressive relapsing MS drugs.
Key Findings
Recent Market Developments
Recent Market Developments (continued)
Defining Healthcare Trends in the Future
Defining Healthcare Trends in the Future (continued)
Companies to Watch
Methodology and Scope
Introduction
Market Overview—Segmentation
Market Overview—Segmentation (continued)
Market Overview—Segmentation (continued)
Prevalence of MS in Major Market
Prevalence of MS in Major Market (continued)
Physician Guidelines to MS Therapy
Competitive Landscape—Count of Marketed and Pipeline Products
MS Therapeutics Competitive Landscape
Marketed Product Analysis
Marketed Product Analysis (continued)
Pipeline Analysis—Products in Clinical Development
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Pipeline Analysis—Products in Clinical Development (continued)
Product Launch Timeline
Patent Expiration Timeline
Marketed Products Clinical Program—AUBAGIO (Teriflunomide)
Marketed Products Clinical Program—Plegridy
Marketed Products Clinical Program—Tysabri
Marketed Products Clinical Program—Tecfidera
Pipeline Products Clinical Program—Ocrelizumab, Ofatumumab
Pipeline Products Clinical Program—Lemtrada
Product Dashboard—Copaxone
Product Dashboard—Avonex (interferon beta-1a)
Product Dashboard—Betaseron/Extavia (interferon beta-1b)
Product Dashboard—Rebif (interferon beta-1a)
Product Dashboard—Tysabri (natalizumab)
Product Dashboard—Gilenya
Product Dashboard—Tecfidera (oral Glatiramer Fumarate)
Product Dashboard—Aubagio (Teriflunomide)
Product Dashboard—Plegridy (BIIB017) (pegylated interferon beta-1a)
Product Dashboard—Lemtrada/Campath 1G (Alemtuzumab)
Product Dashboard—Laquinimod
Product Dashboard—Zenapax (daclizumab)
Product Dashboard—Ocrelizumab
Product Dashboard—AB1010 (Masitinib)
Product Dashboard—Ofatumumab
Conclusions and Recommendations
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Aish Vivekanadan |
| WIP Number | NEC3-01-00-00-00 |
| Is Prebook | No |
A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market
$3,950.00
Special Price $2,962.50 save 25 %